Murakami, Naoka
Hayden, Robert
Hills, Thomas http://orcid.org/0000-0003-0322-5822
Al-Samkari, Hanny http://orcid.org/0000-0001-6175-1383
Casey, Jonathan
Del Sorbo, Lorenzo
Lawler, Patrick R.
Sise, Meghan E.
Leaf, David E. http://orcid.org/0000-0001-7875-090X
Article History
Accepted: 21 September 2022
First Online: 17 October 2022
Change Date: 6 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41581-023-00686-0
Competing interests
: H.A.-S. reports no disclosures relevant to the manuscript; universal disclosures include consultancy (Agios, Dova/Sobi, argenx, Rigel, Novartis, Forma, Moderna) and research funding (Agios, Dova/Sobi, Amgen). P.R.L. is an investigator in the REMAP-CAP ACE2 RAS Domain, which is investigating renin–angiotensin–system-modulating treatments for COVID-19, is supported by a Heart and Stroke Foundation of Canada National New Investigator Award, and has received unrelated consulting honoraria from Novartis, CorEvitas, and Brigham and Women’s Hospital (Boston, MA, USA), as well as unrelated royalties from McGraw-Hill Publishing. L.D.S. is inventor of a patent licensed to SQI Diagnostic and has received unrelated research funding from the Canadian Institutes of Health Research. M.E.S. has received research funding from Gilead Sciences awarded to her institution; additional, unrelated disclosures include research funding from AbbVie, Merck, EMD-Serono, Angion and serving as a scientific advisory board member for Travere and Mallinckrodt. The other authors declare no competing interests.
Free to read: This content has been made available to all.